Sensitivity of Neuroimaging Indicators in Monitoring the Effects of Interferon Gamma Treatment in Friedreich’s Ataxia

Marinela Vavla, Filippo Arrigoni, Nicola Toschi, Denis Peruzzo, Maria Grazia D’Angelo, S. Gandossini, Annamaria Russo, Eleonora Diella, Stefania Tirelli, R. Salati, Alessandra Rufini, Ivano Condò, Roberto Testi, Andrea MartinuzziFrontiers in Neuroscience 2020 · DOI

TL;DR

This study investigated the sensitivity of various neuroimaging techniques (DTI, fMRI, rs-fMRI) and retinal imaging (OCT) to detect changes in Friedreich's Ataxia (FRDA) patients undergoing interferon gamma (IFNγ) treatment. The findings suggest that fMRI and rs-fMRI are promising tools for monitoring treatment response in FRDA clinical trials, as they showed significant modifications that correlated with clinical outcomes, unlike DTI and OCT which showed less sensitivity to treatment effects over the study period.

What Problem Does This Paper Address?

Friedreich's Ataxia (FRDA) is a rare, progressive neurodegenerative disease characterized by motor and sensory deficits. Developing effective treatments is challenging due to the slow progression of the disease and the limited sensitivity of current clinical scales to detect subtle changes. This makes it difficult to accurately assess the efficacy of novel therapeutic strategies in clinical trials. The paper addresses the need for more sensitive, objective biomarkers to monitor disease progression and treatment response in FRDA, focusing on advanced neuroimaging and retinal imaging techniques.

Methods

The study employed a longitudinal design, assessing 11 FRDA patients over a 6-month treatment period with interferon gamma (IFNγ), with follow-up assessments at 6 months post-treatment. The following neuroimaging modalities were used:

  • Diffusion Tensor Imaging (DTI): To assess white matter integrity by measuring fractional anisotropy (FA) and mean diffusivity (MD) in specific brain regions like the superior cerebellar peduncle.
  • Task-Based Functional MRI (fMRI): Patients performed a finger-tapping motor task while their brain activity was measured. Preprocessing involved motion correction, spatial filtering, and a general linear model approach to identify activation patterns.
  • Resting-State fMRI (rs-fMRI): Brain activity was measured while patients were at rest. Preprocessing included motion correction, band-pass filtering, and independent component analysis (ICA) to identify functional networks.
  • Optical Coherence Tomography (OCT): To measure the thickness of the retinal nerve fiber layer (RNFL) and ganglion cell complex (GCC), which are known to be affected in FRDA.

Statistical analysis utilized multivariate linear mixed models to account for within-subject variability and potential confounds like age, sex, and disease duration. Correlations between changes in clinical scores (SARA) and neuroimaging measures were also analyzed.

Datasets

The study utilized data from a cohort of 11 Friedreich's Ataxia patients who participated in an open-label clinical trial. No new datasets were introduced.

Key Insights and Ideas

  • fMRI as a Sensitive Biomarker: Functional MRI (both task-based and resting-state) demonstrated significant changes in brain activity and network organization during and after IFNγ treatment. This suggests fMRI is more sensitive to treatment-induced neural changes than structural DTI or OCT in this timeframe.
  • Correlation with Clinical Outcomes: The observed changes in fMRI activation patterns significantly correlated with improvements in the Scale for the Assessment and Rating of Ataxia (SARA) scores, reinforcing its potential as a clinically relevant biomarker.
  • DTI Shows Slow Progression: DTI revealed a continued, albeit slow, reduction in fractional anisotropy (FA) in the superior cerebellar peduncle, consistent with the known progressive nature of white matter degeneration in FRDA, even during treatment. This suggests DTI might be better suited for tracking long-term disease progression rather than short-term treatment effects.
  • OCT Lacks Sensitivity in This Study: While OCT confirmed the known thinning of the retinal nerve fiber layer, it did not show significant changes over the study period, indicating it may not be a sensitive marker for short-term treatment response in FRDA.
  • Reorganization of Neural Circuits: The fMRI findings suggest that IFNγ treatment may induce a reorganization of neural circuits, particularly in motor and fronto-parietal networks, potentially reflecting adaptive mechanisms or compensatory strategies.

Key Results

  • fMRI: Significant modifications were observed in the left primary motor cortex (task-fMRI) and in the default mode network, sensorimotor network, and left fronto-parietal network (rs-fMRI) between baseline and post-treatment assessments.
  • DTI: A significant reduction in FA was found in the left superior cerebellar peduncle between baseline (T0) and the end of the follow-up period (T12).
  • OCT: No significant changes in RNFL or GCC thickness were observed over the treatment and follow-up periods.
  • Correlation: A significant negative correlation was found between changes in SARA scores and functional activity in the right motor cortex for both dominant and non-dominant hand movements between T0 and T6.

Limitations and Future Work

The authors acknowledge several limitations:

  • Open-label design: The absence of a placebo control group makes it difficult to definitively attribute all observed changes solely to the IFNγ treatment.
  • Small sample size: The study included only 11 patients, which limits the generalizability of the findings and the statistical power to detect subtle changes.
  • Relatively short observation period: The 6-month treatment and 6-month follow-up period might be insufficient to capture the full impact of the treatment or the natural progression of the disease in all aspects.

Future work should focus on:

  • Larger, placebo-controlled trials: To confirm the efficacy of IFNγ and the sensitivity of fMRI as a biomarker.
  • Longer follow-up periods: To better understand the long-term effects of treatment and the natural disease trajectory.
  • Investigating other neuroimaging modalities: Exploring advanced DTI techniques or combining fMRI with other measures to gain a more comprehensive understanding of brain changes.
  • Further validation of fMRI: Establishing fMRI as a reliable and standardized endpoint for FRDA clinical trials.

Summary updated

Abstract

The identification of efficient markers of disease progression and response to possibly effective treatments is a key priority for slowly progressive, rare and neurodegenerative diseases, such as Friedreich's ataxia. Various imaging modalities have documented specific abnormalities in Friedreich's ataxia that could be tracked to provide useful indicators of efficacy in clinical trials. Advanced MRI imaging (diffusion tensor imaging, DTI; functional MRI, fMRI; and resting-state fMRI, rs-fMRI) and retinal imaging (optical coherence tomography, OCT) were tested longitudinally in a small group of Friedreich's ataxia patients participating in an open-label clinical trial testing the safety and the efficacy of 6-month treatment with interferon gamma. While the DTI indices documented the slow progression of fractional anisotropy loss, fMRI and rs-fMRI were significantly modified during and after treatment. The fMRI changes significantly correlated with the Scale for the Assessment and Rating of Ataxia, which is used to monitor clinical response. OCT documented the known thickness reduction of the retinal nerve fiber layer thickness, but there was no change over time. This pilot study provides indications for the potential utility of fMRI and rs-fMRI as ancillary measures in clinical trials for Friedreich's ataxia.
BibTeX
@inproceedings{vavla2020sensitivity,
  author = {Marinela Vavla and Filippo Arrigoni and Nicola Toschi and Denis Peruzzo and Maria Grazia D’Angelo and S. Gandossini and Annamaria Russo and Eleonora Diella and Stefania Tirelli and R. Salati and Alessandra Rufini and Ivano Condò and Roberto Testi and Andrea Martinuzzi},
  title = {{Sensitivity of Neuroimaging Indicators in Monitoring the Effects of Interferon Gamma Treatment in Friedreich’s Ataxia}},
  booktitle = {Frontiers in Neuroscience},
  year = {2020},
  doi = {10.3389/fnins.2020.00872},
}
Figure